Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Change in Account Payables (2019 - 2025)

Allogene Therapeutics (ALLO) has disclosed Change in Account Payables for 7 consecutive years, with $599000.0 as the latest value for Q4 2025.

  • Quarterly Change in Account Payables rose 1661.76% to $599000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$1.2 million through Dec 2025, down 144.73% year-over-year, with the annual reading at -$1.2 million for FY2025, 144.73% down from the prior year.
  • Change in Account Payables hit $599000.0 in Q4 2025 for Allogene Therapeutics, up from -$1.1 million in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $6.8 million in Q2 2024 to a low of -$7.2 million in Q3 2024.
  • Historically, Change in Account Payables has averaged -$256750.0 across 5 years, with a median of -$210000.0 in 2023.
  • Biggest five-year swings in Change in Account Payables: plummeted 666.36% in 2021 and later surged 1661.76% in 2025.
  • Year by year, Change in Account Payables stood at -$2.0 million in 2021, then surged by 243.74% to $2.9 million in 2022, then tumbled by 110.28% to -$302000.0 in 2023, then surged by 111.26% to $34000.0 in 2024, then soared by 1661.76% to $599000.0 in 2025.
  • Business Quant data shows Change in Account Payables for ALLO at $599000.0 in Q4 2025, -$1.1 million in Q3 2025, and -$422000.0 in Q2 2025.